Biotechnology
Neurocrine Biosciences Inc (NBIX)
BUY. 12-month probability-weighted target $170 (+19% vs spot). P/E Multiple explains 81% of Monte Carlo outcome variance.
Biomarin Pharmaceutical Inc (BMRN)
HOLD. 12-month probability-weighted target $58 (+6% vs spot). P/E Multiple explains 77% of Monte Carlo outcome variance.
Exelixis Inc (EXEL)
HOLD. 12-month probability-weighted target $56 (-6% vs spot). P/E Multiple explains 93% of Monte Carlo outcome variance.
United Therapeutics Corporation (UTHR)
HOLD. 12-month probability-weighted target $513 (-7% vs spot). P/E Multiple explains 86% of Monte Carlo outcome variance.
Regeneron Pharmaceuticals Inc (REGN)
SELL. 12-month probability-weighted target $605 (-19% vs spot). P/E Multiple explains 84% of Monte Carlo outcome variance.
Biogen Inc (BIIB)
SELL. 12-month probability-weighted target $191 (-15% vs spot). P/E Multiple explains 64% of Monte Carlo outcome variance.
Vertex Pharmaceuticals Inc (VRTX)
SELL. 12-month probability-weighted target $457 (-10% vs spot). P/E Multiple explains 82% of Monte Carlo outcome variance.
Gilead Sciences Inc (GILD)
SELL. 12-month probability-weighted target $120 (-21% vs spot). P/E Multiple explains 81% of Monte Carlo outcome variance.
AbbVie Inc (ABBV)
SELL. 12-month probability-weighted target $232 (-16% vs spot). P/E Multiple explains 82% of Monte Carlo outcome variance.
Amgen Inc (AMGN)
SELL. 12-month probability-weighted target $350 (-16% vs spot). P/E Multiple explains 80% of Monte Carlo outcome variance.
Repligen Corporation (RGEN)
SELL. 12-month probability-weighted target $125 (-28% vs spot). P/E Multiple explains 76% of Monte Carlo outcome variance.
Halozyme Therapeutics Inc (HALO)
SELL. 12-month probability-weighted target $77 (-30% vs spot). P/E Multiple explains 87% of Monte Carlo outcome variance.
Incyte Corporation (INCY)
Rating suspended since 2026-09-21 — valuation input under review. The rating, price target and expected return are withheld until the name is re-valued; the research on the report page predates the review.
Arrowhead Pharmaceuticals Inc (ARWR)
Rating suspended since 2026-09-29 — valuation input under review. The rating, price target and expected return are withheld until the name is re-valued; the research on the report page predates the review.
Cytokinetics Inc (CYTK)
Rating suspended since 2026-10-03 — valuation method under review. The rating, price target and expected return are withheld until the name is re-valued; the research on the report page predates the review.